Drugs Made In America Acquisition Corp. (DMAAU) Income towards Parent Company (2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Income towards Parent Company came in at $212958.0 in Q4 2025, down 90.25% on a QoQ basis from $2.2 million in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Income towards Parent Company (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 1 years of Income towards Parent Company data on file, last reported at $212958.0 in Q4 2025.
- Quarterly Income towards Parent Company changed N/A year-over-year to $212958.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (changed N/A YoY) and the FY2025 annual result came in at $5.9 million, up 2222.83% from the prior year.
- Income towards Parent Company eased to $212958.0 in Q4 2025, from $2.2 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $2.3 million in Q2 2025 to a low of $212958.0 in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 212,958.00 |
| Sep 30, 2025 | 2.18 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 1.25 Mn |